c-Jun overexpression supercharges CAR-T cells
Welcome to the Mackall Lab
The Mackall lab seeks to discover fundamental principles that control tumor:immune interactions and to apply these insights to develop novel immunotherapies for cancer. Current areas of major focus include in depth studies of the molecular and cellular processes that govern T cell exhaustion, identification of new immune targets expressed by cancer and leveraging emerging synthetic biology platforms to create next generation chimeric antigen receptors that manifest enhanced potency, regulatability, multispecificity and exhaustion resistance. We are a multidisciplinary team, which spans undergraduate researchers, graduate students and postdoctoral fellows, medical students and physicians and early career and senior scientists with expertise in cellular immunology, molecular immunology and oncology, synthetic biology, computational science and clinical investigation. The Mackall laboratory works closely with clinical and translational investigators within the Stanford Center for Cancer Cell Therapy to test novel therapeutics in early phase clinical trials and to identify biomarkers of response and mechanisms of resistance to cancer immunotherapies.
Cellular immunotherapy is a breakthrough because it's a living therapy; the cells that are administered can last in patients for weeks, months, even years.
The Mackall lab is a proud member of St. Baldrick's Stand Up to Cancer Dream Team